The DoJ told the company that it closed its investigation, which concerns “possible violations of the U.S. Foreign Corrupt Practices Act,” Sept. 29, according to the filing.
Grifols wrote that in its decision to not prosecute, the DoJ acknowledged “the full cooperation of Grifols in the investigation,” according to the filing.
In May, Grifols said it invested $50 million in clinical diagnostic tech developer Singulex, giving Grifols a 20% stake in the company.
Grifols’ investment in Singulex now has a fully-diluted pre-money valuation of $200 million, the company said in an SEC filing. Along with the investment, Grifols will be entitled to appoint a director to serve on Singulex’s board, the company said.
The company said Singulex also granted it an exclusive worldwide license for the use and sale of its tech for blood donor and plasma screening. Singulex is developing single molecule counting technology designed to detect biomarkers of diseases that were previously undetectable.